Background Anti‐tumour necrosis factor‐α (TNF α) antibodies are efficacious in
inflammatory bowel disease (IBD). These drugs carry the theoretical risk of malignancy …

Abstract Background and Aims The association between tumour necrosis factor inhibitors
[TNFi] and malignancy in patients with inflammatory bowel disease [IBD] is not well …

Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …

Background Anti‐TNF agents are now widely used in Crohn's disease (CD), and in
ulcerative colitis (UC). Aim To review the safety profile of anti‐TNF agents in all patients …

Tumour necrosis factor alpha (TNF-alpha) inhibitors ensure valuable treatment advantages
for patients with inflammatory bowel diseases (IBD) by offering a more targeted anti …

BACKGROUND & AIMS: Although anti–tumor necrosis factor (TNF) therapy can effectively
treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's …

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Background Anti‐tumour necrosis factor‐alpha agents (anti‐TNF) are effective therapies for
the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. Aim To …

Importance A Cochrane review and network meta-analysis concluded that there is need for
more research on adverse effects, including cancer, after treatment with tumor necrosis …

Anti-tumour necrosis factor-alpha (TNF-a) agents have changed the way of treating
inflammatory bowel diseases (IBD) refractory to conventional medications (corticosteroids …